Déficit en glucose-6-phosphate-déshydrogénase : Questions médicales fréquentes
Nom anglais: Glucosephosphate Dehydrogenase Deficiency
Descriptor UI:D005955
Tree Number:C18.452.648.202.402
Termes MeSH sélectionnés :
Cognitive Dysfunction
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Déficit en glucose-6-phosphate-déshydrogénase : Questions médicales les plus fréquentes",
"headline": "Déficit en glucose-6-phosphate-déshydrogénase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Déficit en glucose-6-phosphate-déshydrogénase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-06",
"dateModified": "2025-05-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Déficit en glucose-6-phosphate-déshydrogénase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Erreurs innées du métabolisme glucidique",
"url": "https://questionsmedicales.fr/mesh/D002239",
"about": {
"@type": "MedicalCondition",
"name": "Erreurs innées du métabolisme glucidique",
"code": {
"@type": "MedicalCode",
"code": "D002239",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C18.452.648.202"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Déficit en glucose-6-phosphate-déshydrogénase",
"alternateName": "Glucosephosphate Dehydrogenase Deficiency",
"code": {
"@type": "MedicalCode",
"code": "D005955",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Thomas Opladen",
"url": "https://questionsmedicales.fr/author/Thomas%20Opladen",
"affiliation": {
"@type": "Organization",
"name": "University Children's Hospital Heidelberg, Department of General Pediatrics, Division of Neuropediatrics and Metabolic Medicine, 69120 Heidelberg, Germany."
}
},
{
"@type": "Person",
"name": "Phillip L Pearl",
"url": "https://questionsmedicales.fr/author/Phillip%20L%20Pearl",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "K Michael Gibson",
"url": "https://questionsmedicales.fr/author/K%20Michael%20Gibson",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacotherapy, Washington State University, Spokane, WA, USA."
}
},
{
"@type": "Person",
"name": "Rebecca D Ganetzky",
"url": "https://questionsmedicales.fr/author/Rebecca%20D%20Ganetzky",
"affiliation": {
"@type": "Organization",
"name": "Division of Human Genetics Children's Hospital of Philadelphia Philadelphia Pennsylvania USA."
}
},
{
"@type": "Person",
"name": "Melissa L DiBacco",
"url": "https://questionsmedicales.fr/author/Melissa%20L%20DiBacco",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant.",
"datePublished": "2022-10-17",
"url": "https://questionsmedicales.fr/article/36251860",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/13506129.2022.2131384"
}
},
{
"@type": "ScholarlyArticle",
"name": "Risk factors for cognitive dysfunction amongst patients with cardiovascular diseases.",
"datePublished": "2024-09-13",
"url": "https://questionsmedicales.fr/article/39346594",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fpubh.2024.1385089"
}
},
{
"@type": "ScholarlyArticle",
"name": "Reward network dysfunction is associated with cognitive impairment after stroke.",
"datePublished": "2023-05-31",
"url": "https://questionsmedicales.fr/article/37307650",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.nicl.2023.103446"
}
},
{
"@type": "ScholarlyArticle",
"name": "Predictors of cognitive dysfunction one-year post COVID-19.",
"datePublished": "2023-01-05",
"url": "https://questionsmedicales.fr/article/36603126",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1037/neu0000876"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cognitive Dysfunction Biomarkers in Patients With Rheumatoid Arthritis: A Systematic Review.",
"datePublished": "2022-12-07",
"url": "https://questionsmedicales.fr/article/36729842",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/RHU.0000000000001888"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies métaboliques et nutritionnelles",
"item": "https://questionsmedicales.fr/mesh/D009750"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies métaboliques",
"item": "https://questionsmedicales.fr/mesh/D008659"
},
{
"@type": "ListItem",
"position": 4,
"name": "Erreurs innées du métabolisme",
"item": "https://questionsmedicales.fr/mesh/D008661"
},
{
"@type": "ListItem",
"position": 5,
"name": "Erreurs innées du métabolisme glucidique",
"item": "https://questionsmedicales.fr/mesh/D002239"
},
{
"@type": "ListItem",
"position": 6,
"name": "Déficit en glucose-6-phosphate-déshydrogénase",
"item": "https://questionsmedicales.fr/mesh/D005955"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Déficit en glucose-6-phosphate-déshydrogénase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Déficit en glucose-6-phosphate-déshydrogénase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Déficit en glucose-6-phosphate-déshydrogénase",
"description": "Comment diagnostiquer le déficit en G6PD ?\nQuels sont les signes cliniques du déficit en G6PD ?\nQuel rôle joue l'historique médical dans le diagnostic ?\nLes tests génétiques sont-ils nécessaires ?\nQuand faut-il consulter un médecin ?",
"url": "https://questionsmedicales.fr/mesh/D005955?mesh_terms=Cognitive+Dysfunction&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Déficit en glucose-6-phosphate-déshydrogénase",
"description": "Quels sont les symptômes courants du déficit en G6PD ?\nComment se manifeste une crise hémolytique ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des symptômes spécifiques aux femmes ?\nLes symptômes peuvent-ils apparaître après un médicament ?",
"url": "https://questionsmedicales.fr/mesh/D005955?mesh_terms=Cognitive+Dysfunction&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Déficit en glucose-6-phosphate-déshydrogénase",
"description": "Comment prévenir les crises hémolytiques ?\nLes vaccinations sont-elles recommandées ?\nFaut-il des tests de dépistage pour les nouveau-nés ?\nComment informer les proches sur la maladie ?\nLes femmes enceintes doivent-elles être testées ?",
"url": "https://questionsmedicales.fr/mesh/D005955?mesh_terms=Cognitive+Dysfunction&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Déficit en glucose-6-phosphate-déshydrogénase",
"description": "Quel est le traitement principal du déficit en G6PD ?\nDes transfusions sanguines sont-elles nécessaires ?\nLes médicaments peuvent-ils aider ?\nComment gérer une crise hémolytique ?\nLe régime alimentaire a-t-il un impact ?",
"url": "https://questionsmedicales.fr/mesh/D005955?mesh_terms=Cognitive+Dysfunction&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Déficit en glucose-6-phosphate-déshydrogénase",
"description": "Quelles sont les complications possibles du déficit en G6PD ?\nLe déficit en G6PD peut-il affecter la grossesse ?\nY a-t-il un risque accru d'infections ?\nLes complications sont-elles réversibles ?\nComment surveiller les complications ?",
"url": "https://questionsmedicales.fr/mesh/D005955?mesh_terms=Cognitive+Dysfunction&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Déficit en glucose-6-phosphate-déshydrogénase",
"description": "Quels sont les facteurs de risque du déficit en G6PD ?\nLes hommes sont-ils plus à risque ?\nL'origine ethnique influence-t-elle le risque ?\nLes nouveau-nés sont-ils à risque ?\nLes médicaments peuvent-ils augmenter le risque ?",
"url": "https://questionsmedicales.fr/mesh/D005955?mesh_terms=Cognitive+Dysfunction&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer le déficit en G6PD ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un test sanguin mesure l'activité de la G6PD pour confirmer le déficit."
}
},
{
"@type": "Question",
"name": "Quels sont les signes cliniques du déficit en G6PD ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent fatigue, jaunisse, et urines foncées après exposition à des déclencheurs."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'historique médical dans le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'historique familial et les antécédents d'hémolyse aident à établir le diagnostic."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils nécessaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques peuvent confirmer le déficit en G6PD, surtout en cas de doute."
}
},
{
"@type": "Question",
"name": "Quand faut-il consulter un médecin ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consultez un médecin si vous présentez des symptômes d'hémolyse ou des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants du déficit en G6PD ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, jaunisse, et douleurs abdominales en cas de crise."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une crise hémolytique ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une crise hémolytique se manifeste par une anémie, une jaunisse et des urines foncées."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent être plus prononcés chez les nourrissons et les jeunes enfants."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux femmes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les femmes peuvent avoir des symptômes moins sévères en raison de la présence de deux chromosomes X."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils apparaître après un médicament ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent déclencher une crise chez les personnes déficientes en G6PD."
}
},
{
"@type": "Question",
"name": "Comment prévenir les crises hémolytiques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez les médicaments et aliments connus pour déclencher des crises chez les déficients."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles recommandées ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations sont recommandées pour prévenir les infections qui peuvent aggraver l'état."
}
},
{
"@type": "Question",
"name": "Faut-il des tests de dépistage pour les nouveau-nés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage néonatal peut identifier les cas de déficit en G6PD précocement."
}
},
{
"@type": "Question",
"name": "Comment informer les proches sur la maladie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éduquez vos proches sur les déclencheurs et les symptômes pour une meilleure gestion."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes doivent-elles être testées ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage peut être utile pour prévenir les complications chez le fœtus."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal du déficit en G6PD ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement consiste principalement à éviter les déclencheurs d'hémolyse."
}
},
{
"@type": "Question",
"name": "Des transfusions sanguines sont-elles nécessaires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des transfusions peuvent être nécessaires en cas d'anémie sévère due à une hémolyse."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de médicaments spécifiques, mais des soins de soutien peuvent être fournis."
}
},
{
"@type": "Question",
"name": "Comment gérer une crise hémolytique ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est crucial de consulter un médecin pour un traitement approprié lors d'une crise."
}
},
{
"@type": "Question",
"name": "Le régime alimentaire a-t-il un impact ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un régime équilibré peut aider, mais il est essentiel d'éviter certains aliments comme les fèves."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles du déficit en G6PD ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'anémie sévère, les infections et des problèmes rénaux."
}
},
{
"@type": "Question",
"name": "Le déficit en G6PD peut-il affecter la grossesse ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut y avoir des risques pour le fœtus, notamment des anémies néonatales."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru d'infections ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes déficientes en G6PD peuvent être plus vulnérables aux infections."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications, comme l'anémie, peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Comment surveiller les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des bilans sanguins réguliers permettent de surveiller l'état et d'anticiper les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque du déficit en G6PD ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, l'origine ethnique et certains médicaments."
}
},
{
"@type": "Question",
"name": "Les hommes sont-ils plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le déficit en G6PD est plus fréquent chez les hommes en raison de son mode de transmission."
}
},
{
"@type": "Question",
"name": "L'origine ethnique influence-t-elle le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le déficit est plus courant chez les personnes d'origine méditerranéenne et africaine."
}
},
{
"@type": "Question",
"name": "Les nouveau-nés sont-ils à risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les nouveau-nés peuvent être à risque, surtout s'ils ont des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils augmenter le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments comme les sulfamides peuvent déclencher des crises chez les déficients."
}
}
]
}
]
}
Cognitive dysfunction is part of the broad spectrum of clinical manifestations in older untreated hereditary transthyretin amyloidosis patients with peripheral polyneuropathy....
The objective of this study is to systematically explore cognitive dysfunction in ATTRV30M amyloidosis patients whose disease course was modified by liver transplant (LT)....
A series of 269 carriers of TTRVal30Met mutation treated with LT underwent a neuropsychological assessment. Clinical charts were reviewed to identify focal neurological episodes (FNEs), cognitive comp...
Cognitive dysfunction was identified in 35 patients (13%)-14 (5%) had mild and 21 (8%) had moderate dysfunction. In comparison to normal cognition, both mild and moderate cognitive dysfunction patient...
Consistent with the natural history of the disease, older age and higher severity of the disease are significantly associated and potentially predictors of cognitive dysfunction in ATTRV30M patients t...
The impact of cardiovascular diseases on cognition raises important research questions. The study aimed to investigate the relationship between demographic data, cardiovascular diseases, kidney diseas...
A cross-sectional study of patients with cardiovascular diseases was performed. The Montreal Cognitive Assessment (MoCA) was applied for cognitive evaluation. Based on MoCA three groups were defined: ...
Of 628 patients, 55.2% had mild CD, and the mean age was 67.95 (SD 9.53) years. Cα and Mω were 0.7, indicating good internal consistency. We found a moderate positive correlation between depression an...
Mild CD was the most common in patients with cardiovascular diseases. Older age, lower education, being a non-smoker, and renal dysfunction were risk factors for both mild and advanced CD. Female gend...
Stroke survivors not only suffer from severe motor, speech and neurocognitive deficits, but in many cases also from a "lack of pleasure" and a reduced motivational level. Especially apathy and anhedon...
(a) To characterize the frequency of objective cognitive deficits and self-perceived cognitive difficulties and (b) to explore demographic and clinical predictors of cognitive dysfunction and cognitiv...
One hundred and ten adults diagnosed with COVID-19 between March and November 2020, aged ≤ 74 years underwent a brief neuropsychological evaluation 12 months after infection, which included: Brief Vis...
Twenty participants (18.2%) had cognitive dysfunction and 36 (33.3%) had cognitive complaints. Cognitive dysfunction was related to lower education, preinfection history of headache/migraine, and acut...
A subset of individuals develops cognitive difficulties in the context of post-COVID syndrome. Results may support the protective effect of education, a known proxy of cognitive reserve. COVID-19 infe...
During the last years, a growing number of studies have investigated the link between cognitive dysfunction and rheumatoid arthritis (RA), highlighting the potential pathogenic role of several clinica...
We performed a systematic review using PRISMA (Preferred Reported Items for Systematic Reviews and Meta-analysis) protocol. A systematic search was conducted in the PubMed/MEDLINE, EMBASE, LILACS, Sco...
Five original studies were included, which provided data from 428 participants. Among plasma proteins, SHH was increased and TTR was reduced in patients with mild cognitive impairment; anti-myelin bas...
Despite the relative scarcity of studies on this subject and the heterogeneity of results, we identified possible biomarkers for cognitive deficits in the RA population. Further longitudinal studies a...
Toll-like receptors (TLRs) are pattern recognition receptors (PRRs) with a well-documented role in the innate and adaptive immune responses. Interestingly, TLR activation has also been linked to sever...
The origin of pre-existing cognitive impairment in stroke patients remains controversial, with a vascular or a degenerative hypothesis....
To determine whether endothelial dysfunction is associated with pre-existing cognitive problems, lesion load and biological anomalies in stroke patients....
Patients originated from the prospective STROKDEM study. The baseline cognitive state, assessed using the IQ-CODE, and risk factors for stroke were recorded at inclusion. Patients with an IQ-CODE scor...
A total of 86 patients were included (52 males; mean age 63.5 ± 11.5 years). Patients with abnormal RHI have hypertension or antihypertensive treatment more often. The baseline IQ-CODE was abnormal in...
A vascular mechanism may be responsible for cognitive problems pre-existing stroke. The measurement of endothelial dysfunction after stroke could become an important element of follow-up, providing an...
There is increasing recognition of the prevalence and impact of cognitive dysfunction (CD) in heart failure (HF) patients. This contemporary review appraises the evidence for epidemiological associati...
CD disproportionately affects heart failure patients, even accounting for known comorbid risk factors, and this may extend to subclinical left ventricular dysfunction. Neuroimaging studies now provide...
Cognitive dysfunction is increasingly recognized as a complication and comorbidity of diabetes, supported by evidence of abnormal brain structure and function. Although few mechanistic metabolic studi...
There is limited data on cognition in patients undergoing peritoneal dialysis (PD). We assessed prevalence and associated risk factors of neurocognitive impairment (NCI) in PD patients....
A cross-sectional cohort study of 149 PD patients at a single centre between 2016 and 2020 who underwent neurocognitive screening at defined intervals by Addenbrooke's Cognitive Examination - Revised ...
Patients on PD performed poorly in ACE-R screening compared to population norms, with discrepancy in all cognitive domains. In patients without CVD, attention and language domains were comparable to n...
Patients on PD have higher prevalence of NCI than the general population, primarily with impairments in memory, fluency and visuospatial reasoning. CVD confers poorer performance in attention and lang...